John N. Allan, MD (Moderator)
Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, NY
DISCUSSION QUESTIONS
Consider the data for the SEQUOIA (NCT03336333), ELEVATE-TN (NCT02475681), and CLL14 (NCT02242942) trials:
- How do you interpret the efficacy and safety data for each study?
- Based on the results from ELEVATE-TN, would you consider adding a CD20 antibody to acalabrutinib (Calquence)?
- Based on the results from CLL14, would you consider VenG (venetoclax [Venclexta] plus obinutuzumab [Gazyva])? In which patient type?
- What are your thoughts on BTKi (Bruton tyrosine kinase inhibitor) plus venetoclax continuous therapy?
John Allan, MD: Considering these data updates, is there a superior drug in your mind, or a superior approach? When you’re looking at VenG…